ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-market Study of AMAP Receptor Antagonists for Epilepsy Patients in Hong Kong

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03457961
Recruitment Status : Recruiting
First Posted : March 8, 2018
Last Update Posted : March 9, 2018
Sponsor:
Information provided by (Responsible Party):
Dr. Howan Leung, Prince of Wales Hospital, Shatin, Hong Kong

Brief Summary:

Background:

Epilepsy is a chronic neurological disease which affects approximately 70,000 patients in Hong Kong and 50 billion people worldwide. Among these patients one-third remained unresponsive to antiepileptic agents. Continual drug manipulation is an essential therapeutic option for these patients with refractory epilepsy. In particular, rational polytherapy has become the mainstay of treatment for the sub-group of patients who have failed two or more antiepileptic drugs (AEDs).

A substantial amount of research has shown that N-methyl-D-aspartate receptors (NMDA) may play a key role in the pathophysiology of several neurological diseases, including epilepsy. Animal models of epilepsy and clinical studies demonstrate that NMDA receptors activity and expression can be altered in association with epilepsy and particularly in some specific seizure types. NMDA receptor antagonists have been shown to have antiepileptic effects in both clinical and preclinical studies. There is some evidence that conventional antiepileptic drugs may also affect NMDA receptor function.

Aims:

To investigate the medium to long-term effects of AMPA/NMDA receptor antagonist in an Asian cohort as there is a relative lack of clinical data in this population To explore the efficacy of AMPA/NMDA receptor antagonist in patients with partial onsets seizures that may secondarily generalize and the specific side effects of AMPA/NMDA receptor antagonist in relation to behavioral problems.

Methods:

A semi-prospective design is adopted to recruit patients who are indicated and started on AMPA/NMDA receptor antagonist aged 12 or above in Hong Kong. This study will collect information about demographic details, medical history and seizure information. Assessment of seizure frequency is based on seizure diary and interviews with family members. Physical examination, electrocardiogram and other medical information relevant to the follow-up of the patient will be collected.


Condition or disease Intervention/treatment
Focal Epilepsy Generalized Epilepsy Partial Seizures, Simple Drug: Perampanel

Detailed Description:

Epilepsy is a chronic neurological disease which affects approximately 70,000 patients in Hong Kong and 50 billion people worldwide. Among these patients, one-third remained unresponsive to antiepileptic agents. Continual drug manipulation is an essential therapeutic option for these patients with refractory epilepsy. In particular, rational polytherapy has become the mainstay of treatment for the sub-group of patients who have failed two or more antiepileptic drugs (AEDs).

Using AEDs with different mechanisms of action is a strategy adopted by many doctors around the world. In this regard, perampanel (PER) is an agent which is first in its class, with specific antagonistic action on ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor of post-synaptic neurons. The pharmacokinetics of PER suggested that it has a half-life of approximately 105 hours and the steady-state concentrations that can be reached in 14 days. PER is approximately 95% bound to plasma proteins. This metabolism is mediated by CYP 3A4 or CYP 3A5. The usual dosage of PER is between 2mg and 12 mg. PER can be administered once daily.

A total of five clinical studies demonstrated the efficacy of PER among patients with refractory epilepsy. These were all double-blind studies and all of them evaluated the 50% responder rate as a seizure outcome. The corresponding risk ratio for 50% responder rates for 4mg, 8mg and 12mg were 1.54, 1.8 and 1.72. The most common treatment-emergent adverse effects were dizziness, drowsiness, headache, fatigue, nasopharyngitis. The pooled results suggested that a higher dose was more efficacious if the side effects could be tolerated. There was an on-going study on the use of PER among patients with secondarily generalized seizures. Perampanel has been approved in many countries such as USA, EU, Australia, Canada, Switzerland, Singapore, and Malaysia, as an adjunctive therapy for refractory partial seizures with or without secondary generalisation among patients above 12 years of age.

A substantial amount of research has shown that N-methyl-D-aspartate receptors (NMDA) may play a key role in the pathophysiology of several neurological diseases, including epilepsy. Animal models of epilepsy and clinical studies demonstrate that NMDA receptors activity and expression can be altered in association with epilepsy and particularly in some specific seizure types. NMDA receptor antagonists have been shown to have antiepileptic effects in both clinical and preclinical studies. There is some evidence that conventional antiepileptic drugs may also affect NMDA receptor function.


Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post-market Study of AMAP Receptor Antagonists for Epilepsy Patients in Hong Kong
Actual Study Start Date : July 23, 2016
Estimated Primary Completion Date : March 1, 2019
Estimated Study Completion Date : July 1, 2019


Group/Cohort Intervention/treatment
Adjunctive Perampanel
A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
Drug: Perampanel
This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
Other Name: Fycompa




Primary Outcome Measures :
  1. Efficacy end-points [ Time Frame: 16 weeks ]
    The primary efficacy end-points evaluates seizure frequency (per month) in week 0 (baseline) and week 16 (maintenance phase). The investigators will used those seizure frequencies (per month) to calculate the percentage change from baseline to maintenance phase for each subject and categories: no change, between 0 to 50% decrease, 50% to 75% decrease, 75% to 100% decrease.

  2. Seizure freedom rate in study population [ Time Frame: 16 weeks ]
    The proportion of subjects achieving seizure freedom during the maintenance period will be documented. The percentage of seizure free days in the maintenance phase will also be collected. The investigators will report the seizure freedom rate for the present study population and the average days of achieving seizure freedom.


Secondary Outcome Measures :
  1. Psychiatric and behavioral adverse events [ Time Frame: 16 weeks ]
    The investigators would use the Neuropsychiatric Inventory Questionnaire (NPI) with 12 domains to evaluate the neuropsychiatric events in week 0 (baseline) and week 16 (maintenance phase). The investigators will record each symptom severity (rated 1 occasional to 4 very frequent) and frequency (rated 1 mild to 3 severe).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients (diagnosed epilepsy with simple partial seizure) who have a baseline seizure rate of more than 2 months would be provided perampanel as adjunctive treatment.
Criteria

Inclusion Criteria:

  1. Subject aged 12 years or above
  2. Subject has a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
  3. Subjects who have a baseline seizure rate of more than 2 per month in the eight week period preceding the start of AMPA / NMDA receptor antagonist
  4. No seizure free period longer than 21 days during the eight week period before AMPA receptor antagonist was started
  5. Patients who already had neuropsychiatric inventory completed twice during the treatment period spanning at least 16 weeks.

Exclusion Criteria:

  1. Subjects with idiopathic generalised epilepsy (for example, juvenile myoclonic epilepsy and absence epilepsy)
  2. Patients who only suffer from isolated auras
  3. Baseline creatinine clearance of less than 50ml/min
  4. Severe hepatic impairment with ALT three times the upper limits of normal
  5. Significant psychiatric conditions before the start of AMPA / NMDA receptor antagonist
  6. Progressive neurodegenerative conditions
  7. Active history of malignancy
  8. History of severe haematological conditions or serious blood dyscrasias
  9. Corrected QT interval more than 450 milli-second on ECG
  10. Substance abuse
  11. Pregnancy, breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03457961


Contacts
Contact: Ka Lai YIP 85235053856 Hannahykl@cuhk.edu.hk

Locations
Hong Kong
Prince of Wales Hospital Recruiting
Hong Kong, Hong Kong, 0000
Contact: Ka Lai YIP    +85235053856    Hannahykl@cuhk.edu.hk   
Principal Investigator: Ho Wan Leung         
Sponsors and Collaborators
Chinese University of Hong Kong
Investigators
Principal Investigator: Ho Wan Leung Chinese University of Hong Kong

Publications:
Responsible Party: Dr. Howan Leung, Associate consultant, Prince of Wales Hospital, Shatin, Hong Kong
ClinicalTrials.gov Identifier: NCT03457961     History of Changes
Other Study ID Numbers: 2016-HL-001
First Posted: March 8, 2018    Key Record Dates
Last Update Posted: March 9, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: This is a cohort study for perampanel in Hong Kong. There is no plan to make individual participant data to share. The results would be shared in publications. Electronic data will be saved in secured computer of the individual sites with restricted access. The anonymous data will be managed installed for developing future studies.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dr. Howan Leung, Prince of Wales Hospital, Shatin, Hong Kong:
Perampanel
focal onset seizure
epilepsy

Additional relevant MeSH terms:
Epilepsy
Seizures
Epilepsies, Partial
Epilepsy, Generalized
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms